Brokers Set Expectations for Xeris Biopharma FY2029 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Analysts at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for shares of Xeris Biopharma in a research report issued on Friday, November 6th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.63 per share for the year, down from their prior estimate of $0.65. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.13 per share.

XERS has been the subject of several other research reports. Oppenheimer reissued an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a research note on Friday, November 6th. Barclays raised their price target on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Piper Sandler reiterated a “neutral” rating and set a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a report on Friday, November 6th. Finally, Leerink Partners boosted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Xeris Biopharma presently has an average rating of “Moderate Buy” and an average price target of $16.20.

Xeris Biopharma Stock Down 0.2%

XERS opened at $15.83 on Monday. The company has a quick ratio of 1.02, a current ratio of 2.15 and a debt-to-equity ratio of 3.89. The firm has a market cap of $2.89 billion, a P/E ratio of -316.54 and a beta of 0.61. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $16.11. The business’s fifty day simple moving average is $9.92 and its 200 day simple moving average is $7.70.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. The company had revenue of $107.23 million during the quarter, compared to analysts’ expectations of $101.68 million.

Insiders Place Their Bets

In other news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the sale, the insider owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total value of $312,250.00. Following the completion of the sale, the insider directly owned 1,559,208 shares of the company’s stock, valued at approximately $19,474,507.92. This represents a 1.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 168,332 shares of company stock valued at $1,678,971 in the last quarter. 4.35% of the stock is currently owned by company insiders.

Institutional Trading of Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the business. KBC Group NV purchased a new stake in Xeris Biopharma in the 1st quarter valued at about $27,000. GK Wealth Management LLC purchased a new position in shares of Xeris Biopharma during the 3rd quarter worth about $32,000. Allworth Financial LP purchased a new position in shares of Xeris Biopharma during the 2nd quarter worth about $34,000. State of Wyoming purchased a new position in shares of Xeris Biopharma during the 2nd quarter worth about $52,000. Finally, William Mack & Associates Inc. purchased a new position in shares of Xeris Biopharma during the 3rd quarter worth about $53,000. 42.75% of the stock is owned by institutional investors and hedge funds.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The firm kept its Buy rating and $18 target, a positive signal about its earnings outlook.
• Positive Sentiment: Other recent coverage includes a “Moderate Buy” consensus rating, an upgrade from Wall Street Zen, and Oppenheimer reiterating “Outperform.” Xeris Biopharma Stock Rated Moderate Buy Xeris Biopharma Upgraded at Wall Street Zen Oppenheimer Reiterates Outperform Rating
• Neutral Sentiment: The short-interest item describes a “large increase” but reports total short interest of zero shares. That contradiction makes the figure difficult to interpret and not a dependable catalyst.
• Neutral Sentiment: Analyst views are not unanimous: Piper Sandler reiterated a Neutral rating, and a separate headline characterized HC Wainwright’s earnings outlook as weaker. The specific figures provided, however, show HC Wainwright raising estimates. Piper Sandler Reiterates Neutral Rating HC Wainwright Expects Weaker Earnings

Xeris Biopharma Company Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.